LAB Q1 2025 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$388M

Q1 2025 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$41M-10.4% YoY

Gross Profit

$20M48.4% margin

Operating Income

-$33M-80.8% margin

Net Income

-$26M-63.8% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-12.7%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$35M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$580M

Total Liabilities

$125M

Stockholders' Equity

$455M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$46M	-10.4%
Gross Profit	$20M	$24M	-18.4%
Operating Income	-$33M	-$60M	+45.2%
Net Income	-$26M	-$32M	+19.0%

Revenue Segments

Product And Service

$40M39%

Product

$22M22%

Service

$18M17%

Consumables

$14M14%

Instruments

$8M8%

Collaboration and Other Revenue

$956,0001%

Geographic Segments

Americas

$19M47%

EMEA

$13M31%

Asia Pacific

$9M23%